Search results for "leukemia"

showing 10 items of 976 documents

Steroidal saponins from Raphia vinifera and their cytotoxic activity

2020

Abstract Phytochemical analysis of the fruits of Raphia vinifera led to the isolation of four new steroidal saponins (1–4), along with six known secondary metabolites (6–10). The structures of the isolated compounds were determined based on the analyses of NMR and mass spectrometric data, and chemical degradation reactions. Among the compounds tested, 1 and 4 showed the most promising cytotoxic activity against the drug-sensitive CCRF-CEM leukemia cell lines, with IC50 values of 3.55 µM and 7.14 µM, respectively.

Models MolecularClinical BiochemistryMolecular ConformationAntineoplastic Agents030209 endocrinology & metabolismArecaceaeBiochemistryLeukemia cell line03 medical and health sciences0302 clinical medicineEndocrinologyCell Line TumorIc50 valuesHumansCytotoxic T cellCytotoxicityMolecular BiologyPharmacologybiologyChemistryOrganic ChemistrySaponinsbiology.organism_classificationMass spectrometricRaphia viniferaPhytochemicalBiochemistry030220 oncology & carcinogenesisSteroidsSteroids
researchProduct

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

2004

Fms-like tyrosine kinase 3 (FLT3) receptor mutations as internal tandem duplication (ITD) or within the kinase domain are detected in up to 35% of patients with acute myeloid leukemia (AML). N-benzoyl staurosporine (PKC412), a highly effective inhibitor of mutated FLT3 receptors, has significant antileukemic efficacy in patients with FLT3-mutated AML. Mutation screening of FLT3 exon 20 in AML patients (n = 110) revealed 2 patients with a novel mutation (Y842C) within the highly conserved activation loop of FLT3. FLT3-Y842C-transfected 32D cells showed constitutive FLT3 tyrosine phosphorylation and interleukin 3 (IL-3)-independent growth. Treatment with PKC412 led to inhibition of proliferat…

Models MolecularImmunologyBiologymedicine.disease_causeBiochemistryCell Linechemistry.chemical_compoundMicefluids and secretionshemic and lymphatic diseasesProto-Oncogene ProteinsmedicineSTAT5 Transcription FactorAnimalsHumansTyrosinePhosphotyrosineMutationCell CycleMyeloid leukemiaReceptor Protein-Tyrosine Kinaseshemic and immune systemsTyrosine phosphorylationCell BiologyHematologymedicine.diseaseMilk ProteinsProtein Structure TertiaryDNA-Binding ProteinsEnzyme ActivationLeukemiaLeukemia Myeloid AcutechemistryGene Expression Regulationfms-Like Tyrosine Kinase 3embryonic structuresFms-Like Tyrosine Kinase 3MutationCancer researchTrans-ActivatorsTyrosineSignal transductionTyrosine kinaseSignal TransductionBlood
researchProduct

Interleukin-6 and Soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis

1998

T HE INTERLEUKIN-6 (IL-6) family of cytokines acts via receptor complexes that contain at least one subunit of the signal transducing protein gp130.[1][1] The family comprises IL-6, IL-11, ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), leukemia inhibitory factor (LIF), and oncostatin M

Models Molecularendocrine systemmedicine.medical_specialtyRecombinant Fusion ProteinsImmunologyMice TransgenicLeukemia inhibitory factor receptorOncostatin MBiologyCiliary neurotrophic factorBiochemistryDesigner DrugsMiceStructure-Activity RelationshipAntigens CDInternal medicineCytokine Receptor gp130medicineAnimalsHumansInterleukin 6Membrane GlycoproteinsInterleukin-6Oncostatin MOncostatin M receptorCell DifferentiationReceptors InterleukinCell BiologyHematologyHematopoietic Stem CellsGlycoprotein 130Receptors Interleukin-6Molecular biologyHematopoiesisEndocrinologyLiverSolubilitybiology.proteinSignal transductionPeptidesLeukemia inhibitory factorSpleenBlood
researchProduct

Zinc oxide nanorod based immunosensing platform for the determination of human leukemic cells.

2019

Zinc oxide (ZnO) based nanostructures owing unique physical properties – high photoluminescence, bio- compatibility and other characteristics, therefore, they attract attention as building blocks suitable for biosensor development. In this research as a target we have used human leukemic cell line IM9 (IM9). IM9 was derived from the patient with a multiple myeloma and expressed cluster of differentiation proteins СD19 on the surface of 85–95% here investigated cancer cells. As a control sample healthy human's peripheral blood mononuclear cells (PBMC) were used and the expression of CD19 protein was found only in 5–9% of these cells. Two types of antibodies labeled by f…

Monoclonal antibodymedicine.drug_class02 engineering and technologyCell SeparationMonoclonal antibody01 natural sciencesCD19Analytical ChemistryFlow cytometrychemistry.chemical_compoundHuman lymphocytesmedicineHumansFlow cytometryZnO-nanorodsFluorescein isothiocyanatePhotoluminescenceCells CulturedImmunoassayB-LymphocytesLeukemiaNanotubesCluster of differentiationmedicine.diagnostic_testbiology010401 analytical chemistryhemic and immune systemsВ-lymphoblast cells021001 nanoscience & nanotechnologyFlow CytometryMolecular biologyhumanities0104 chemical scienceschemistryCell cultureCancer cell:NATURAL SCIENCES [Research Subject Categories]biology.proteinAntibodyZinc Oxide0210 nano-technologyhuman activitiesBiomarkersTalanta
researchProduct

Evolutionary dynamics of imatinib-treated leukemic cells by stochastic approach

2008

The evolutionary dynamics of a system of cancerous cells in a model of chronic myeloid leukemia (CML) is investigated by a statistical approach. Cancer progression is explored by applying a Monte Carlo method to simulate the stochastic behavior of cell reproduction and death in a population of blood cells which can experience genetic mutations. In CML front line therapy is represented by the tyrosine kinase inhibitor imatinib which strongly affects the reproduction of leukemic cells only. In this work, we analyze the effects of a targeted therapy on the evolutionary dynamics of normal, first-mutant and cancerous cell populations. Several scenarios of the evolutionary dynamics of imatinib-tr…

Monte Carlo simulation stochastic approach Evolutionary dynamicsMutation rate87.23.kgmedicine.drug_classQC1-999medicine.medical_treatmentPopulationGeneral Physics and AstronomyBiologyTyrosine-kinase inhibitorTargeted therapyhemic and lymphatic diseasesmedicine87.10.mncomplex systemsQuantitative Biology - Populations and EvolutioneducationEvolutionary dynamicseducation.field_of_studycancer evolutionPhysicsstochastic dynamics87.19.xjPopulations and Evolution (q-bio.PE)Myeloid leukemiaImatinibSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)FOS: Biological sciencesCancer cellCancer research87.10.rtmedicine.drugOpen Physics
researchProduct

Effect of zinc on oropharyngeal mucositis in children with acute leukemia undergoing chemotherapy

2020

Background Oropharyngeal mucositis (OM) is one of the main side-effects of oncological therapy. There is no treatment to prevent its occurrence, but some zinc-based therapies have been proven to help in decreasing its intensity. The objective of this study was to determine the effect of zinc in OM in children with acute leukemia in the early stages of oncological treatment. Material and Methods This quasi-experimental study evaluated OM in 2 groups (control group: conventional hospital management, and experimental group: administration of 50 mg of zinc gluconate daily plus conventional hospital management). OM severity was recorded at a two-month follow-up. Results Forty-nine patients (26 i…

MucositisOropharyngeal mucositismedicine.medical_specialtyAdolescentLymphoblastic Leukemiamedicine.medical_treatmentchemistry.chemical_elementAntineoplastic AgentsZincGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineMucositisHumansChildGeneral DentistryStomatitisAcute leukemiaChemotherapyPain scoreLeukemiabusiness.industryResearchMean age030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Medically compromised patients in Dentistrymedicine.diseaseZincOtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASFemaleSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Differentiation of Murine C2C12 Myoblasts Strongly Reduces the Effects of Myostatin on Intracellular Signaling

2020

Alongside in vivo models, a simpler and more mechanistic approach is required to study the effects of myostatin on skeletal muscle because myostatin is an important negative regulator of muscle size. In this study, myostatin was administered to murine (C2C12) and human (CHQ) myoblasts and myotubes. Canonical and noncanonical signaling downstream to myostatin, related ligands, and their receptor were analyzed. The effects of tumorkines were analyzed after coculture of C2C12 and colon cancer-C26 cells. The effects of myostatin on canonical and noncanonical signaling were strongly reduced in C2C12 cells after differentiation. This may be explained by increased follistatin, an endogenous blocke…

Muscle Fibers Skeletallcsh:QR1-502lihaksetlcsh:MicrobiologyArticleTGF-BETA SUPERFAMILYCell LineMyoblastsMicetumorkineCell Line TumorfollistatinAnimalsHumansCANCER CACHEXIAskeletal muscleMUSCLE ATROPHYlihassolutSmadsoluviestintäRECEPTORCell DifferentiationIN-VITROMyostatinmusculoskeletal systemMAPKActivinsLEUKEMIA INHIBITORY FACTORACTIVIN-AinflammationCulture Media ConditionedCELLSPROTEIN-SYNTHESISmyotubeGROWTH1182 Biochemistry cell and molecular biologyproteiinit3111 BiomedicinecocultureSignal Transduction
researchProduct

Cancer growth dynamics: stochastic models and noise induced effects

2009

In the framework of the Michaelis‐Menten (MM) reaction kinetics, we analyze the cancer growth dynamics in the presence of the immune response. We found the coexistence of noise enhanced stability (NES) and resonant activation (RA) phenomena which act in an opposite way with respect to the extinction of the tumor. The role of the stochastic resonance (SR) in the case of weak cancer therapy has been analyzed. The evolutionary dynamics of a system of cancerous cells in a model of chronic myeloid leukemia (CML) is investigated by a Monte Carlo approach. We analyzed the effects of a targeted therapy on the evolutionary dynamics of normal, first‐mutant and cancerous cell populations. We show how …

Mutation rateStochastic modellingmedicine.medical_treatmentMyeloid leukemiaCancerStochastic resonance (sensory neurobiology)BiologyBioinformaticsmedicine.diseaseTargeted therapyCancer cellCancer researchmedicineEvolutionary dynamics
researchProduct

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

2009

Abstract In acute myeloid leukemia (AML), internal tandem duplications (ITDs) of the juxtamembrane (JM) of FLT3 have been shown to play a crucial role in driving proliferation and survival of the leukemic clone. Here, we report the identification of FLT3_ITD mutations located in non-JM domains of the FLT3-receptor. This novel type of FLT3_ITD mutation was found in 216 of 753 (28.7%) of unselected FLT3_ITD-positive AML cases. An FLT3 receptor harbouring a prototypic non-JM ITD (FLT3_ITD627E) mediated constitutive phosphorylation of FLT3 and of STAT5, suggesting that non-JM ITDs confer constitutive activation of the receptor. FLT3_ITD627E induced transformation of hematopoietic 32D cells and …

MutationImmunologyClone (cell biology)MedizinMyeloid leukemiaCell BiologyHematologyBiologymedicine.disease_causeBiochemistryMolecular biologyReceptor tyrosine kinasehemic and lymphatic diseasesTrk receptormedicinebiology.proteinPhosphorylationReceptorSTAT5
researchProduct

DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of th…

2011

Abstract Abstract 415 Background: Alteration of DNA methylation, a hallmark of epigenetic modification, is currently discussed as one important pathomechanism in leukemogenesis. Using a next-generation sequencing approach, a frameshift mutation of the gene encoding the DNA methyltransferase (DNMT3A) in an acute myeloid leukemia (AML) case was identified. DNMT3A catalyses the addition of a methyl group to the cytosine residue of CpG dinucleotides, thereby affecting promoter methylation status and gene expression. Subsequent sequencing analysis in an independent cohort of 288 AML patients (pts) revealed DNMT3A mutations (DNMT3Amut) in 22% of the pts; mutations were associated with intermediat…

MutationNPM1medicine.medical_specialtyImmunologyCytogeneticsMyeloid leukemiaCell BiologyHematologyBiologymedicine.disease_causeBiochemistryIDH2Molecular biologyFrameshift mutationCEBPAmedicineMissense mutationBlood
researchProduct